TNGX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tango Therapeutics Inc (TNGX) is not a strong buy at the moment for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. While the stock has bullish technical indicators and positive analyst sentiment, the lack of recent news catalysts, weak financial performance, and neutral trading sentiment from insiders and hedge funds suggest a cautious approach. The pre-market price decline and absence of strong proprietary trading signals further support holding off on immediate investment.
The stock shows bullish technical indicators: MACD is positive at 0.198, RSI is neutral at 65.981, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are Pivot: 19.212, R1: 21.141, S1: 17.283, R2: 22.333, S2: 16.091. However, the pre-market price is down 1.31%, indicating short-term weakness.
Analysts have consistently raised price targets, with the highest target at $27, and maintain Buy or Outperform ratings. The company's lead oncology program, vopimetostat, has potential first-in-class and best-in-class opportunities, with promising clinical trial collaborations.
The company reported zero revenue in Q4 2025, with a YoY drop of -100%. EPS also declined by -14.71% YoY. Trading sentiment from insiders and hedge funds is neutral, and there is no recent news or congress trading data to act as a catalyst.
In Q4 2025, revenue dropped to $0 (-100% YoY), net income improved slightly to -$38.75M (+2.86% YoY), and EPS declined to -0.29 (-14.71% YoY). Gross margin remains at 100%, but the lack of revenue and negative earnings are concerning.
Analysts are optimistic, with multiple firms raising price targets recently. The highest price target is $27 (H.C. Wainwright), and the lowest is $19 (Mizuho). Analysts highlight the potential of vopimetostat and expect positive Phase I readouts in 2026.
